The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.

[1]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[2]  C. M. Aldaz,et al.  Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. , 2008, Oral oncology.

[3]  P. Edwards,et al.  Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX , 2008, Genes, chromosomes & cancer.

[4]  S. Thorgeirsson,et al.  Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma , 2008, Hepatology.

[5]  O. Bruland,et al.  Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas , 2008, Journal of Neuro-Oncology.

[6]  Thomas D. Schmittgen,et al.  Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.

[7]  Xu Yongjian,et al.  Deletion and mutation of WWOX exons 6–8 in human non-small cell lung cancer , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].

[8]  R. Gomez,et al.  Association between decreased WWOX protein expression and thyroid cancer development. , 2007, Thyroid : official journal of the American Thyroid Association.

[9]  J. Llovet,et al.  Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase 3 Randomized, Placebo-Controlled Trial , 2007 .

[10]  G. Stein,et al.  Targeted deletion of Wwox reveals a tumor suppressor function , 2007, Proceedings of the National Academy of Sciences.

[11]  C. Croce,et al.  WWOX Expression in Different Histologic Types and Subtypes of Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[12]  D. Iliopoulos,et al.  Inhibition of Breast Cancer Cell Growth In vitro and In vivo: Effect of Restoration of Wwox Expression , 2007, Clinical Cancer Research.

[13]  Thiru V. Lakshman,et al.  Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity , 2007, International journal of cancer.

[14]  R. Flavell,et al.  Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure , 2006, Gut.

[15]  J. Ludes-Meyers,et al.  WWOX protein expression in normal human tissues , 2006, Journal of Molecular Histology.

[16]  N. Kaplowitz,et al.  c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. , 2006, Gastroenterology.

[17]  D. Iliopoulos,et al.  A role for the WWOX gene in prostate cancer. , 2006, Cancer research.

[18]  D. A. Gomes,et al.  Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas , 2006, International journal of cancer.

[19]  R. Richards,et al.  Common chromosomal fragile sites and cancer: focus on FRA16D. , 2006, Cancer letters.

[20]  R. Richards,et al.  FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila , 2006, Oncogene.

[21]  L. Hsu,et al.  Light-induced retinal damage involves tyrosine 33 phosphorylation, mitochondrial and nuclear translocation of WW domain-containing oxidoreductase in vivo , 2005, Neuroscience.

[22]  Q. Hong,et al.  WOX1 Is Essential for Tumor Necrosis Factor-, UV Light-, Staurosporine-, and p53-mediated Cell Death, and Its Tyrosine 33-phosphorylated Form Binds and Stabilizes Serine 46-phosphorylated p53* , 2005, Journal of Biological Chemistry.

[23]  T. Kuroki,et al.  Common Fragile Genes and Digestive Tract Cancers , 2005, Surgery Today.

[24]  James L Mohler,et al.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.

[25]  M. Macleod,et al.  Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR , 2005, Molecular carcinogenesis.

[26]  A. Cleton-Jansen,et al.  Expression analysis of candidate breast tumour suppressor genes on chromosome 16q , 2005, Breast Cancer Research.

[27]  D. Amadori,et al.  WWOX gene restoration prevents lung cancer growth in vitro and in vivo , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Hsu,et al.  WOX1 Is Essential for UVB Irradiation–Induced Apoptosis and Down-Regulated via Translational Blockade in UVB-Induced Cutaneous Squamous Cell Carcinoma In vivo , 2005, Clinical Cancer Research.

[29]  D. Iliopoulos,et al.  Concordant loss of fragile gene expression early in breast cancer development , 2005, Pathology international.

[30]  G. Mills,et al.  WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome , 2005, BMC Cancer.

[31]  A. Paige,et al.  WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. , 2005, International journal of oncology.

[32]  K. Mimori,et al.  Components of DNA Damage Checkpoint Pathway Regulate UV Exposure–Dependent Alterations of Gene Expression of FHIT and WWOX at Chromosome Fragile Sites , 2005, Molecular Cancer Research.

[33]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[34]  Dimitrios Iliopoulos,et al.  Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer , 2005, Oncogene.

[35]  L. Hsu,et al.  17β-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo , 2005, Oncogene.

[36]  J. Ludes-Meyers,et al.  Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma , 2004, British Journal of Cancer.

[37]  Fang Wang,et al.  Parkin gene alterations in hepatocellular carcinoma , 2004, Genes, chromosomes & cancer.

[38]  R. Ashfaq,et al.  FHIT mRNA and protein expression in hepatocellular carcinoma , 2004, Modern Pathology.

[39]  Y. Pekarsky,et al.  Loss of WWOX Expression in Gastric Carcinoma , 2004, Clinical Cancer Research.

[40]  A. Chinnaiyan,et al.  Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23–qter and identifies underlying candidate tumor suppressor genes in prostate cancer , 2004, Oncogene.

[41]  D. Iliopoulos,et al.  The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma , 2004, Cancer.

[42]  C. Croce,et al.  The Tumor Suppressor Gene WWOX at FRA16D Is Involved in Pancreatic Carcinogenesis , 2004, Clinical Cancer Research.

[43]  M. Fiorentino,et al.  Predictive Value of Biological Markers for Hepatocellular Carcinoma Patients Treated with Orthotopic Liver Transplantation , 2004, Clinical Cancer Research.

[44]  David I. Smith,et al.  hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. , 2004, Gastroenterology.

[45]  H. Aburatani,et al.  An opposing view on WWOX protein function as a tumor suppressor. , 2003, Cancer research.

[46]  C. Croce,et al.  Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. , 2003, Molecular cancer research : MCR.

[47]  J. Ludes-Meyers,et al.  WWOX, the common chromosomal fragile site, FRA16D, cancer gene , 2003, Cytogenetic and Genome Research.

[48]  David I. Smith,et al.  Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer , 2003, Genes, chromosomes & cancer.

[49]  David I. Smith,et al.  Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer* , 2003, Journal of Biological Chemistry.

[50]  M. Czaja.  The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[51]  R. Schwabe,et al.  c‐Jun‐N‐terminal kinase drives cyclin D1 expression and proliferation during liver regeneration , 2003, Hepatology.

[52]  N. Chang,et al.  JNK1 Physically Interacts with WW Domain-containing Oxidoreductase (WOX1) and Inhibits WOX1-mediated Apoptosis* , 2003, The Journal of Biological Chemistry.

[53]  C. Croce,et al.  WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. , 2003, Cancer research.

[54]  B. Song,et al.  Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. , 2003, Molecular pharmacology.

[55]  E. Calhoun,et al.  The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1 , 2002, Genes, chromosomes & cancer.

[56]  Tomoyuki Masuda,et al.  M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan , 2002, Hepatology.

[57]  C. Croce,et al.  Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. , 2002, Cancer research.

[58]  H. Prydz,et al.  Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors , 2002, Oncogene.

[59]  N. Nishida,et al.  Prognostic Impact of Multiple Allelic Losses on Metastatic Recurrence in Hepatocellular Carcinoma after Curative Resection , 2002, Oncology.

[60]  N. Chang.  A potential role of p53 and WOX1 in mitochondrial apoptosis (review). , 2002, International journal of molecular medicine.

[61]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Brenner,et al.  WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. , 2001, Cancer research.

[63]  D J Porteous,et al.  WWOX: A candidate tumor suppressor gene involved in multiple tumor types , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Zucman‐Rossi,et al.  Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma , 2001, Oncogene.

[65]  C. Croce,et al.  The tumor spectrum in FHIT-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Kawasaki,et al.  Loss of heterozygosity of the mannose 6-phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular carcinoma. , 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

[67]  C J Kemp,et al.  p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. , 2001, Experimental cell research.

[68]  K. Buetow,et al.  Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1–24.1 , 2001, Genes, chromosomes & cancer.

[69]  J. Heath,et al.  Hyaluronidase Induction of a WW Domain-containing Oxidoreductase That Enhances Tumor Necrosis Factor Cytotoxicity* , 2001, The Journal of Biological Chemistry.

[70]  L. Roberts,et al.  The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. , 2000, Genomics.

[71]  R. Richards,et al.  Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. , 2000, Human molecular genetics.

[72]  A. Bednarek,et al.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. , 2000, Cancer research.

[73]  J. Sgouros,et al.  A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. , 2000, Cancer research.

[74]  S. Thorgeirsson,et al.  Alterations of the FHIT gene in human hepatocellular carcinoma. , 2000, Cancer research.

[75]  S. Finkelstein,et al.  Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  N. Nishida,et al.  Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma , 1992, International journal of cancer.

[77]  Michiie Sakamoto,et al.  Characterization of High‐Molecular‐Mass Forms of Basic Fibroblast Growth Factor Produced by Hepatocellular Carcinoma Cells: Possible Involvement of Basic Fibroblast Growth Factor in Hepatocarcinogenesis , 1991, Japanese journal of cancer research : Gann.

[78]  S. Hirohashi,et al.  Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. , 1991, Cancer letters.

[79]  W. Birchmeier,et al.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells , 1991, The Journal of cell biology.